A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma

作者：Abei Masato; Okumura Toshiyuki; Fukuda Kuniaki; Hashimoto Takayuki; Araki Masahiro; Ishige Kazunori; Hyodo Ichinosuke; Kanemoto Ayae; Numajiri Haruko; Mizumoto Masashi; Sakae Takeji; Sakurai Hideyuki; Zenkoh Junko; Ariungerel Gerelchuluun; Sogo Yu; Ito Atsuo; Ohno Tadao; Tsuboi Koji^*

来源：Radiation Oncology, 2013, 8(1): 239.

DOI：10.1186/1748-717X-8-239

• Proton-beam radiotherapy
• Hepatocellular carcinoma
• Immunotherapy
• Immunoadjuvant

Background: Proton-beam radiotherapy (PBT) has been shown to be effective to hepatocellular carcinoma (HCC) as a nonsurgical local treatment option. However, HCC still remains as one of the most difficult cancers to be cured because of frequent recurrences. Thus, methods to inhibit the recurrence need to be explored. To prevent the HCC recurrence, we here report on a prospective phase I study of %26apos;in situ%26apos; tumor vaccination using CalTUMP, a newly developed immunoadjuvant consisting of BCG extract bound to hydroxyapatite and microparticulated tuberculin, following local PBT for HCC. %26lt;br%26gt;Methods: Patients with locally advanced recurrent HCC, which had been heavily pretreated with various treatments, were enrolled. PBT was performed with the conventional method to the target HCC. Subsequently, CalTUMP was injected into the same irradiated-tumor three times at one-week intervals. Three dose-levels of CalTUMP (1/10, 1/3, and 1/1) were administered to 3 patients each. Vital signs, blood samples, ultrasound, and computed tomographic scans were monitored to evaluate the safety. %26lt;br%26gt;Results: Three intratumoral injections of CalTUMP following PBT (median dose: 72.6 GyE) were accomplished in 9 patients. Transient low-grade fever and minor laboratory changes were observed in 7 patients after CalTUMP injections. No other treatment-related adverse events were observed. Median progression-free survival was 6.0 months (range: 2.1-14.2) and 4 patients were progression-free for more than 1 year. %26lt;br%26gt;Conclusions: Intratumoral injection of CalTUMP following PBT was feasible and safe in patients with heavily pre-treated HCC. Further clinical studies to evaluate the efficacy of this in situ tumor vaccination are warranted.

• 出版日期2013-10-16